The latest featured news from Adrenal World News
From the desk of Lewis Blevins, MD – There is no such thing as adrenal fatigue. Period. I’ve seen plenty of patients over my career who have been referred for this “condition.” It’s not a
From the desk of Lewis Blevins, MD – I remember, in the mid-1990s, when a paper was published indicating that food dependent hypercortisolism was due aberrant GIP receptor expression on the adrenal glands. Eating activates
From the desk of Lewis Blevins, MD, AWN cofounder – I have a vague recollection of considering the possibility of the coexistence of primary aldosteronism and hypercortisolism in adrenal hyperplasia during my fellowship in Endocrinology
In this recent Medscape InDiscussion podcast Dr. Marwah Abdalla welcomes PWN’s Dr. Lewis Blevins to talk about secondary hypertension. This episode focuses on Cushing syndrome, an often overlooked cause of secondary hypertension. We’ll discuss why
Genetic Syndromes Association with Pheochromocytomas and Paragangliomas From Jennifer Perkins, MD, MBA, Co-director of UCSF’s endocrine neoplasia program, Executive Medical Director ambulatory, and PWN contributor – Pheochromocytomas (PCCs) are catecholamine-secreting tumors arising from chromaffin cells
A commentary on adrenal masses by Dr. Lewis Blevins, AWN cofounder – My experience with adrenal disorders is that radiologists often miss things. Some adrenal nodules are not even reported on CT scans of the
Mineralocorticoid Replacement Therapy From the desk of Lewis S. Blevins Jr., M.D. – Treatment of partial and complete aldosterone deficiency seems to be an arena where inexperienced physicians miss the mark more often than not.
I first learned of this condition in 1990 during my fellowship training in endocrinology at The Johns Hopkins Hospital. I
Dr. Lewis Blevins talks with Dr. Iacopo Chiodini at The Endocrine Society Meeting in San Francisco, California to discuss his presentation illustrating the benefits of adrenalectomy in patients with MACS.
In today’s podcast, Dr. Lewis Blevins discusses relacorilant, a drug currently in development by Corcept Therapeutics for the treatment of hypercortisolism. Clinical trials to date have shown encouraging results, with improvements in blood pressure, glucose control, weight, and body composition.
Through our conversations with leading adrenal and pituitary experts, physicians, nurses, industry executives, researchers, patient advocates, and other key stakeholders, we gain unique insights from the fascinating world of adrenal and pituitary disease research and treatment.